Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome-Reference-Cited by-同舟云学术

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome

Published:2024-07-09 Issue:9 Volume:59 Page:1332-1334
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Schroeder Jan Christian^ORCID,Mix Lucas^ORCID,Faustmann Philipp,Weller Jan Frederic,Fehn Adrian,Phely Laurent,Riedel Andreas,Vogel Wichard,Faul Christoph,Lengerke Claudia^ORCID,Bethge Wolfgang Andreas^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02365-5.pdf

Reference12 articles.

1. de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62. https://doi.org/10.1182/blood-2016-06-724500

2. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. https://doi.org/10.1182/blood.2022016867

3. Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer. 2007;110:345–52. https://doi.org/10.1002/cncr.22779

4. Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, et al. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2012;18:466–72. https://doi.org/10.1016/j.bbmt.2011.09.006

5. Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2012;18:1415–21. https://doi.org/10.1016/j.bbmt.2012.05.003